<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02497716</url>
  </required_header>
  <id_info>
    <org_study_id>17992</org_study_id>
    <secondary_id>2015-000962-76</secondary_id>
    <nct_id>NCT02497716</nct_id>
  </id_info>
  <brief_title>Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children</brief_title>
  <official_title>Single-dose Study Testing Rivaroxaban Granules for Oral Suspension Formulation in Children From 2 Months to 12 Years With Previous Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetic profile of rivaroxaban administered as granules for
      suspension formulation and to document safety and tolerability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2015</start_date>
  <completion_date type="Actual">May 22, 2018</completion_date>
  <primary_completion_date type="Actual">May 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (area under the curve)</measure>
    <time_frame>4x within 8 hrs post study drug administrationh and 1x between 24-28h after administration</time_frame>
    <description>Only PK will be tested in central lab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum observed drug concentration)</measure>
    <time_frame>4x within 8 hrs post study drug administrationh and 1x between 24-28h after administration</time_frame>
    <description>Only PK will be tested in central lab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time (PT)</measure>
    <time_frame>Pre-administration, if not done within the past 10 days, and then 24-28 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Pre-administration, if not done within the past 10 days, and then 24-28 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of major bleeding and clinically relevant non-major bleeding</measure>
    <time_frame>From dose administration until follow up call on day 8+3</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, open label study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939</intervention_name>
    <description>Single dose of reconstituted rivaroxaban granules</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with an age ≥2 months and weight between 3 and &lt;12 kg, who have completed
             anticoagulant treatment at least 10 days prior to the planned study drug
             administration.

               -  Gestational age at birth of at least 37 weeks

               -  Oral feeding/ nasogastric/ gastric feeding for at least 10 days

          -  Normal PT and aPTT within 10 days prior to planned study drug administration

          -  Written informed consent provided and, if applicable, child assent provided

        Exclusion Criteria:

          -  Active bleeding or high risk for bleeding, contraindicating anticoagulant therapy

          -  Planned invasive procedures, including removal of central lines, within 24 hours
             before and after single dose intake

          -  An estimate glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2

          -  Hepatic disease which is associated either with:

               -  coagulopathy leading to a clinically relevant bleeding risk, or alanine
                  aminotransferase (ALT) &gt; 5x upper level of normal (ULN), or

               -  total bilirubin &gt; 2x ULN with direct bilirubin &gt; 20% of the total.

          -  Platelet count &lt; 50 x 10^9/L

          -  Hypertension (defined as systolic and/or diastolic blood pressure &gt;95th percentile for
             age)

          -  Concomitant use of strong inhibitors of both CYP3A4 and P-glycoprotein, e.g., all
             human immunodeficiency virus protease inhibitors and the following azoleantimycotic
             agents: ketoconazole, itraconazole, voriconazole, and posaconazole, if used
             systemically (fluconazole is allowed)

          -  Concomitant use of strong inducers of CYP3A4, e.g., rifampicin, rifabutin,
             phenobarbital, phenytoin and carbamazepine

          -  Inability to cooperate with the study procedures

          -  Hypersensitivity to rivaroxaban

          -  Participation in a study with an investigational drug other than rivaroxaban or a
             medical device within 30 days prior to treatment

          -  History of gastrointestinal disease or surgery associated with impaired absorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital For Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUS Lastenklinikka</name>
      <address>
        <city>HUS</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turun yliopistollinen keskussairaala, kantasairaala</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve - Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker les enfants malades - Paris</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Semmelweis/ Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. di Padova</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan de Déu</name>
      <address>
        <city>Esplugues de LLobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ciutat Sanitària i Universitaria de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Ireland</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 12, 2015</study_first_submitted>
  <study_first_submitted_qc>July 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>April 14, 2019</last_update_submitted>
  <last_update_submitted_qc>April 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

